KMT2D and acute myeloid leukemia: KO-539 (Figure 5) induces complete remission (CR) in two out of six patients with relapsed/refractory acute myeloid leukemia (R/R AML), including a minimal residual disease (MRD)-negative CR in a NPM1-mutated AML patient co-mutated for DNMT3A and KMT2D [115].